Receptor antagonist adenosine A2A.

A compound having the structural formula A ** (See formula) ** or a pharmaceutically acceptable salt or solvate of such, wherein: R is selected from the group consisting of R1-furanyl-, R1-thienyl-, R1--pyridyl-, -oxazolyl--R1, R1-pyrrolyl- and R2-aryl; X is - (CH2) n-, Y is a piperidinyl, pyrrolidinyl or azepanyl with an aryl or heteroaryl fused to two adjacent carbon atoms on Y, wherein X is bonded to the N atom of the piperidinyl, pyrrolidinyl or azepanyl; Q represents 1 to 4 substituents which may be the same or different and are independently selected from the group consisting of hydrogen, cycloalkyl, cycloheteroalkyl, amino, aryl, aralkyl, heteroaryl, alkyl, CF3, CN, halogen, NO2, alkoxy, alkoxyalkoxy, cycloalkylalkoxy, acyloxy, alkylamino, acylamino, alkylsulfonamino, alkylaminosulfonyl, dialkylaminosulfonyl, NH2SO2-, and hydroxy; n is 1 to 4; R1 represents 1-3 substituents which may be the same or different and are independently selected from the group consisting of hydrogen, alkyl, CF3, halogen and NO2 and R2 represents 1-3 substituents, which may be the same or different, and independently selected from the group consisting of hydrogen, alkyl, CF3, halogen, NO2, alkoxy, acyloxy, alkylamino, acylamino, alkylsulfonamido, alkylaminosulfonyl, dialkylaminosulfonyl and hydroxyl. wherein said compound is not a compound wherein: (i) X is C2-C4 alkyl; (Ii) R is Ra-furanyl-, Ra-thienyl-, Ra--pyridyl-, -oxazolyl--Ra, Ra-pyrrolyl- or Rb-phenyl, wherein Ra represents 1-3 substituents independently selected from hydrogen, C1- alkyl C6, -CF3, halogen and NO2, and Rb represents 1-3 substituents independently selected from hydrogen, C1-C6 alkyl, -CF3, halogen, -C1-C6 alkyl, C1-C6 alkylamino, di- ((C1-C6 alkyl )) amino and hydroxy; and (iii) is QY- ** (See formula) ** or ** (See formula) ** 2/1 where R9 represents independently selected from hydrogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, -CF3 and (C1-C6) alkoxy- (C1-C6).